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Animal modelThe triosephosphate isomerase (TPI) functions at a metabolic cross-road ensuring the rapid equilibration of
the triosephosphates produced by aldolase in glycolysis, which is interconnected to lipid metabolism, to
glycerol-3-phosphate shuttle and to the pentose phosphate pathway. The enzyme is a stable homodimer,
which is catalytically active only in its dimeric form. TPI deﬁciency is an autosomal recessive multisystem
genetic disease coupled with hemolytic anemia and neurological disorder frequently leading to death in
early childhood. Various genetic mutations of this enzyme have been identiﬁed; the mutations result in
decrease in the catalytic activity and/or the dissociation of the dimers into inactive monomers. The
impairment of TPI activity apparently does not affect the energy metabolism at system level; however, it
results in accumulation of dihydroxyacetone phosphate followed by its chemical conversion into the toxic
methylglyoxal, leading to the formation of advanced glycation end products. By now, the research on this
disease seems to enter a progressive stage by adapting new model systems such as Drosophila, yeast strains
and TPI-deﬁcient mouse, which have complemented the results obtained by prediction and experiments
with recombinant proteins or erythrocytes, and added novel data concerning the complexity of the
intracellular behavior of mutant TPIs. This paper reviews the recent studies on the structural and catalytic
changes caused by mutation and/or nitrotyrosination of the isomerase leading to the formation of an
aggregation-prone protein, a characteristic of conformational disorders.
© 2009 Elsevier B.V. All rights reserved.1. Introduction: major characteristics of triosephosphate
isomerase (TPI)
Human TPI is encoded by a single gene located at chromosome
12p13 and is expressed in all tissues. Its amino acid sequence is highly
conserved among all known TPI proteins [1,2]. The gene product is a
housekeeping enzyme, the physiological function of which is to adjust
the rapid equilibrium between the triosephosphates, dihydroxyace-
tone phosphate (DHAP) and glyceraldehyde-3-phosphate, produced
by aldolase in glycolysis, which is interconnected to lipid metabolism,
to glycerol-3-phosphate shuttle and to the pentose phosphate
pathway.
TPI is a stable homodimer of two 27-kDa subunits consisting of 248
amino acids. The spatial structure of TPI is one of the most
characterized ones as the ﬁrst example of a (β/α)8 barrel fold
(“TIM-barrel”) [3] (for reviews, see [4,5]). The α-helices and β-sheets
are linked by loop regions. Three loops of the N-terminal half of the
molecule are involved in the intersubunit interactions, other three
ones participate in the active site [1]. One of them is a ﬂexible loop, theAP, dihydroxyacetone phos-
n end product; Aβ, amyloid β-
ory.
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ll rights reserved.movement of which is necessary for providing the so called “closed”
(liganded) state of the enzyme [6]. The 3D structure of human
recombinant isomerase was also obtained by crystallography at a
resolution of 2.8 Å [1]. Three residues, Lys13, His95 and Glu165, form
the active site. However, it was proposed that residues indispensable
for enzyme activity exist throughout the C-terminal region of the
protein, with the possible exception of the ultimate few amino acids.
TPI is catalytically active only in its dimeric form. The crucial role of
the dimeric form both in the catalytic function and the stability was
clearly demonstrated by Mainfroid et al. [7] by producing recombi-
nant enzymes with “artiﬁcial”mutations Met14Gln and/or Arg98Gln.
These mutations at the dimer interface decreased the stability of the
isomerase due to its dissociation into inactive monomers.2. TPI deﬁciency
TPI deﬁciency is the most severe glycolytic enzymopathy, the only
one which is lethal, frequently in early childhood. In spite of the
efforts to understand the basis of this disease, our knowledge is rather
limited due to its rarity and/or the failure of its recognition.
Homozygotes and compound heterozygotes manifest not only
congenital hemolytic anemia, as in the case of more frequent
disorders of glycolytic enzymes, but their symptoms include neuro-
logical dysfunctions as cardiomyopathy and progressive neuromus-
cular impairment. No effective therapy is available for TPI deﬁciency.
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disorder, characterized by decreased enzyme activity, which is
accompanied by the elevation of the substrate, DHAP, level. This
phenomenon is the most distinct in erythrocytes, where the multiple
consumption of DHAP does not hold; thus, in the case of the lack of TPI
activity it is a dead-end product.
The most frequent missense mutation detected in TPI-deﬁcient
patients occurs at codon 104 in the TPI gene (Glu104Asp mutant),
which accounts for approximately 80% of mutant alleles within
patients with clinical TPI deﬁciency [2,8]. Glu104Asp arose as a single
mutation in a common ancestor of the affected families [2,8]. This
mutation is not only the most common but also causes the most
severe symptoms. Some additional mutations have been identiﬁed so
far with infrequent occurrence, mostly in compound heterozygotes,
coupled with Glu104Asp mutation [2,9]. A unique case is that of the
compound heterozygote Hungarian brothers, identiﬁed by S. Hollan;
both brothers carry the mutations of Phe240Leu and Glu145Stop;
however, neurological symptoms have developed only at the younger
one [10].
Extensive genetic and biochemical work was carried out to
reveal the basis of this disease. The studies at atomic and molecular
levels focused primarily on the structural background of the
decreased enzyme activity. At system level, the main questions
arisen are whether the decreased activity can maintain the normal
glycolytic ﬂux; why it results in the extreme elevation of the DHAP
level; and how the mutation is connected with the neurological
symptoms.
The doyen of TPI deﬁciency research, A. Schneider, reviewed the
accumulated data from hematological point of view and discussed the
genetic background and molecular aspects of the disease, too [2].
More recently, we have summarized the molecular, structural and
energetic aspects of the disease, providing a system level analysis of
the deﬁciency, as well [9].
A couple of papers, using yeast, ﬂy and mouse models of TPI
deﬁciency, have been recently published, which signiﬁcantly contrib-
ute to our understanding the structural and functional consequences
of the mutations. A view seems to be emerging that the reduction in
the stability of the dimeric enzyme due to the mutations at the
subunit interface can be a crucial component in the etiology of the
illness. The new results support our former view that TPI deﬁciency is
rather a conformational than a metabolic disease, although accumu-Table 1
Characterization of missense TPI mutations of patients and of animal models.
Mutation Effect of the mutation ona Recombinant enzyme Ye
Substrate binding Dimer interface Activity loss Instability Ac
Met Init Lys Nonsense mutation n.d. n.d. No
Cys41Tyr + + n.d. n.d. −
Ala62Asp − + n.d. n.d. n.
Gly72Ala + ++ n.d. n.d. n.
Glu104Asp − ++ − f ++ f −
Gly122Arg − − n.d. n.d. −
Val154Met − − n.d. n.d. n.
Ile170Val ++ − n.d. n.d. +
Val231Met + + n.d. n.d. n.
Phe240Leu + − + g + g −
Asp49Gly d − ++ n.d n.d. n.
Met82Thr e − ++ n.d n.d. n.
n.d. – no data; −, none; +, moderate; ++, severe; +++, complete loss.
a Based on Schneider [2].
b From Ralser et al. [16].
c From Schneider [2] and Orosz et al. [9].
d Mouse model [25].
e Fly model [18–20] in which Met80 corresponds to human Met82.
f From Rodríguez-Almazán et al. [13].
g From Orosz et al. [11].
h No patients. Found in a population survey in healthy heterozygotes. Indirect activity anlation of toxic metabolites might also play a role in its clinical
manifestations.
3. Functional and structural consequences of the mutations
The human pathogenic mutations are not restricted to a speciﬁc
domain or region of the enzyme. Bioinformatic analysis, based on the
3D structure of the wild-type enzyme, was used by Schneider [2] to
explain the structural and catalytic properties of the mutant enzymes
observed in the patients' hemolysates. He mapped the amino acid
residues as well as the ﬁrst- and second-degree contacts of all of the
residues comprising the functional domains of the enzyme. Mutation
sites coupled with the substrate binding site (the active center) would
manifest activity decrease, while those in or interacting with the di-
mer interface are expected to exhibit molecular instability manifesting
as thermolability coupled with catalytic abnormalities.
Cys41Tyr, Gly72Ala, Ile170Val, Val231Met and Phe240Leu muta-
tions were suggested to interact with the substrate binding site [2]
(Table 1). Among these amino acid residues, Ile170 is not only in
the neighborhood of Glu165 of the active site but is also part of the
ﬂexible loop, the conformation of which alters during the ligand
binding [6]. Indeed, signiﬁcant activity decrease was observed in all
these cases [9].
Mutations Cys41Tyr, Ala62Asp, Gly72Ala, Glu104Asp and Val231-
Met were supposed to inﬂuence the contact surface of the dimeric TPI
[2] (Table 1). The involvement of amino acids Glu104 and Gly72Ala in
the stabilization of dimeric form is clearly supported by the 3D
structural model of the wild-type enzyme (Fig. 1), which explains the
signiﬁcant instability and decreased activity of these mutants. The
effects of the Cys41Tyr and Val231Met mutations, which were
suggested to inﬂuence both the dimer interface and the active site,
are not so trivial; however, beside the activity decrease, thermolabil-
ity was also demonstrated in the four cases when investigated. (No
stability study has been carried out in a recently published case with
Ala62Asp mutation.)
However, it seems that the static 3D model, based on crystal
structures of thewild-type enzyme, does not capture all the functional
relationships between the mutations and catalytic defects in the case
of TPI deﬁciency. Thermolability was also found for the Phe240Leu
[11] and Gly122Arg [12] mutations, which were not suggested to
affect the dimer interface. Moreover, in two cases (occurring only inastb model Hemolysate c Neurological
disorderc
Reference
tivity loss Instability Activity loss Instability
t viable +++ n.d. ++ [44]
− + + + [8]
d. n.d. ++ n.d. n.d. [45]
d. n.d. ++h ++ h ?h [46]
++ +/++ ++ ++ [14]
− − + ?h [12]
d. n.d. ++h ++h ?h [46]
− ++ − − [8]
d n.d. + + + [47]
− ++ + +/− [10]
d n.d. +d ++d n.d. [25]
d n.d. n.d n.d. +e [18–20]
d stability data.
Fig. 1. Schematic ribbon diagram of the crystal structure of recombinant wild-type human TPI based on Mande et al. [1]. Lys13, His95 and Glu165 are the active site residues (black).
Amino acid residues substituted by inherited mutations in human patients and heterozygous carriers are Cys41 (A, orange), Ala62 (B, yellow), Gly72 (B, blue), Glu104 (B, red),
Gly122 (B, lilac), Val 154 (A, yellow), Ile170 (A, blue), Val231 (A, red) and Phe240 (A, lilac). Asp49 (B, orange) and Met82 (B, green) (in ﬂy Met80) were mutated in mouse and ﬂy
models of TPI deﬁciency, respectively. The ﬁgure was generated by the DeepView/Swiss-PdbViewer v3.7 software (http://www.expasy.org/spdbv/) using the recombinant human
TPI structure (1HTI pdb ﬁle).
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suggested (cf. Table 1) and the reported deﬁciency of these mutations
remains unexplained. There are two plausible explanations for these
discrepancies: (i) some mutations may cause local or global
conformational changes that are not evident using the static model;
and (ii) protein activity and stability were typically assayed in
hemolysates of the patients where intracellular associations could
further alter either structure or function of the enzyme.
4. New knowledge from studies with recombinant mutant
enzymes
Despite extensive work that has been carried out on the mutant
enzymes in hemolysates, until very recently only the Phe240Leumutant
TPI was studied in recombinant form [11]. This kind of investigation can
provide direct information whether intrinsic alterations of the enzyme
or external factors are responsible for the discrepancies between
prediction and measurements made in cell extracts.
Now, the characteristics of the Glu104Asp recombinant enzyme
have been ascertained and compared with those of the recombinant
wild-type human TPI [13]. Direct evidence for the structural changes
in the dimer interface of TPI due to the Glu104Asp mutation was
obtained from the 3D structure of the recombinant mutant enzyme by
x-ray analysis (at 1.85-Å resolution) [13]. Formerly, it was proposed
on the basis of the crystal structures of wild-type TPI [1,3] that a
counterbalance of charges would lower the stability of the dimer, with
an eventual perturbation of the local structure of the active site [1,14].
However, the structure of Glu104Aspmutant human TPI [13] revealed
that the geometry of the catalytic residues was not modiﬁed and that
the most important consequence of the Glu104Asp mutation is the
disruption of a conserved water network that spans the dimer
interface and appears to be essential for maintaining the stability of
TPI dimers. This mutation, affecting the dimer interface, does not
inﬂuence the catalytic activity per se; the kinetic parameters of the
mutant and wild-type recombinant enzymes are nearly identical [13].Yet, decreased TPI activity was detected in the patients' hemolysates
(cf. Table 1), probably due to the dissociation of the enzyme into
inactive monomers. This idea was further supported by measure-
ments of the stability and reactivation of thewild-type and Glu104Asp
mutant recombinant enzymes from unfolded monomers, which
revealed that the formation of active dimers from unfolded inactive
monomers was impeded in the case of the mutant enzyme as
compared to that of the wild type [13].
Moreover, thermal denaturation data obtained by circular dichro-
ism spectroscopy, differential scanning calorimetry and enzyme
activity measurements revealed the extreme thermolability of the
Glu104Asp mutant [13]. Namely, it was fully inactivated in 4 min at
48 °C, while in the case of the Phe240Leu recombinant mutant it
occurred in 30 min at 52 °C [13,11]. In addition, the two different
mutations resulted in different thermal denaturation routes deter-
mined by differential scanning calorimetry; Phe240Leu mutant has
two transitions, whereas the Glu104Asp mutant has only one, at a
signiﬁcantly lower temperature. These differences can also be
interpreted on the basis of the distinct sites of the mutations. The
replacement of Glu at position 104 counteracts with the intersubunit
interaction, while, according to our molecular dynamics simulation, a
distinct conformational state in the active-site region was seen due to
the Phe240Leu mutation, but it did not extend to the subunit contact
surface [15]. Although the Phe240Leu mutant is also somewhat
thermolabile in comparison with the wild type, the local conforma-
tional changes may not be extended to the dimer interface and do not
inﬂuence signiﬁcantly the dimerization. However, this mutant is
expected to inﬂuence the catalytic activity [2,15]. Indeed, the activity
of the recombinant Phe240Leu mutant was 30% of that of the wild
type [11].
5. New models for studying TPI deﬁciency
Research on TPI deﬁciency recently has entered a new stage by
adapting new model systems, such as Drosophila, yeast strains and
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mental data for the in vivo behavior of TPI mutants. The high degree of
TPI sequence conservation from bacteria to human and the high
degree of structural similarity observed in TPI crystal structures [1]
allow one to evaluate pathologically relevant information on the
effects of speciﬁc mutations in TPI from these models. This is an
important issue since patients' symptoms often depend on their
genetic background and environmental factors, which are, of course,
not present in experiments using recombinant enzymes.
5.1. Yeast models
Ralser et al. [16] exploited a well-established yeast system, which
allowed them to decrease these additional effects and to study the
enzymatic and structural properties of wild-type and pathogenic TPI
variants and to characterize the effect of the mutations at different
regions (catalytic site or dimer interface) of TPI.
For studying the catalytic properties, they used a single gene
replacement approach. A Δtpi1 strain deleted for the yeast TPI1 gene
was generated and transformed for the expression of human wild-
type or six representative pathogenic TPI mutants. With the
exception of a TPI with a nonsense mutation (Met Init Lys), all
yeast strains containing mutant TPI were viable on glucose media
demonstrating the functional activity of these enzymes. The Δtpi1
cells expressing the mutant TPIs, Cys41Tyr, Glu104Asp, Gly122Arg or
Phe240Leu, exhibited catalytic activity in vivo that was comparable
to that of the cells expressing wild-type protein. This observation
differs from that obtained with hemolysates of patients and with
recombinant Phe240Leu mutant but is in agreement with that
obtained with the recombinant Glu104Asp TPI. The Ile170Val mutant
showed a strong reduction in catalytic activity (Table 1), which was
not due to reduction of enzyme level but the decreased enzymatic
activity per se. This observation resembles the one obtained by
prediction based upon 3D structure and by measurement of activity
in hemolysate (Table 1). The residual activity (about 30%) was still
sufﬁcient to suppress the growth defect of Δtpi1 yeast cells on
glucose medium [16].
To investigate whether the mutations within the TPI gene affect
the dimerization behavior of the protein, the yeast two-hybrid system
was used. The yeast strain L40ccua was transformed with a bait
construct encodingwild-type TPI in combination with prey constructs
encoding the wild-type or one of the abovementioned mutant TPIs.
The relative activity of the lacZ reporter gene, which indicates the
relative strength of a protein–protein (in this case the subunit-
subunit) interaction [17], was measured by using a β-galactosidase
activity assay. It signiﬁcantly decreased (less than 20% of the control)
only in yeast co-expressing the wild-type (bait) and Glu104Asp
(prey) TPI demonstrating the impaired dimerization. Similar effect
was established when the formations of the homodimeric Glu104Asp
or its heterodimers with the other mutants were tested. The only
exception was the Ile170Val mutant which stabilized somewhat the
heterodimer [16]. These results may also explain the fact that TPIs of
the compound heterozygote patients carrying Glu104Asp and another
mutation are also thermolabile except the combination of Glu104Asp
and Ile170Val (cf. [9]).
The results indicate that the yeast system, although did not mimic
all consequences of the mutations, was suitable to model the
consequences of the two most characteristic ones: the aberrant
dimerization and the decreased activity of the Glu104Asp and the
Ile170Val mutants, respectively.
5.2. Drosophila model
The architecture of the ﬂy nervous system is similar to that of
mammals; thus, ﬂy models are often used to study the progression of
various diseases. By using forward genetic screens, two independentresearch groups identiﬁed the same TPI-deﬁcient ﬂy mutant (named
sugarkill or wasted away) with phenotypes showing analogous
symptoms and characteristics to those of human TPI deﬁciency,
including progressive locomotor impairment, temperature sensitivity,
vacuolar neuropathology and severely reduced life span [18,19].
This recessive hypomorphic TPI mutant carries the Met80Thr
mutation; Met80 corresponds to Met82 in human TPI [18,19]. This
mutation affects a conserved methionine residue that resides at the
TPI dimer interface (Table 1). Therefore, not surprisingly, the above-
mentioned characteristic features of the mutant ﬂy show the best
parallel with the Glu104Asp human mutation. Mutation at the dimer
interface results in the instability of the isomerase leading to the
proposal that dimer instability underlies the temperature sensitivity
observed in the ﬂies [18]. Despite this logic suggestion, further
investigation by the same group showed that the mutant protein
maintained its dimeric state when the temperature of the whole ﬂy
extract was elevated [20]. This unexpected stability of the mutant
isomerase could be due to its heteroassociations to unrelated proteins
as demonstrated earlier [21]. Biochemical studies on mutant Droso-
phila models demonstrated that the phenotype was not the result of
impaired bioenergetics [18,19], which resembles the human data
[2,10,22]. Although markedly reduced lactic acid level was detected
[18], ATP [19] and phosphocreatine [18] levels remained normal and
increased, respectively.
The mRNA and protein levels of TPI were investigated in TPIsugarkill
mutant ﬂy [20] at room temperature and at 29 °C (a physiologically
relevant temperature for Drosophila). The level of mRNA was not
reduced at any temperature examined; however, the protein level
was reduced in temperature-dependent manner: 73% and 98%
reduction was detected at room temperature and at 29 °C, respec-
tively, as compared to that of the wild-type ﬂy. The severity of this
reduction was antagonized by decreasing temperature, consistent
with other phenotypes observed in TPIsugarkill mutant. This phenom-
enon could be attributed to the instability and/or the active
proteolytic degradation of TPIsugarkill protein. Indeed, genetic inhibi-
tion of the 20S proteasome core resulted in modest increase in
TPIsugarkill protein level [20], which may indicate the misfolding of TPI
by this mutation.
5.3. Mouse model
A breakthrough could be expected in TPI deﬁciency research if a
stable mouse model was established. The high degree of sequential
identity (95%) and structural similarity of the mammalian enzymes,
the expected resemblance of the pathological consequences of the
mutation in mouse and human and the availability of blood, and
especially, of brain samples are obvious advantages in comparison
with yeast or ﬂy models.
Former attempts generally resulted in homozygous lethal muta-
tions due to a total lack of TPI activity [23] or mice which did not show
any symptoms but decreased enzyme activity [24]. Very recently, a
TPI mutant, Tpi1a-m6Neu, with approximately 13% residual enzyme
activity in blood of homozygotes compared with that of the wild-type
has been produced by triethylenemelamine treatment [25]. The
homozygous animals are viable with full fertility and complete
penetrance of the mutation. Sequence analysis revealed an Asp to
Gly substitution at codon 49. This residue is 100% conserved in
mammals. Asp49 was suggested to directly participate in the dimer
interface [2]. As expected, the mutant TPI exhibited molecular
instability manifested as thermolability. TPI heat lability of erythro-
cytes at 50 °C in homozygous mutants is so strong that the activity is
reduced to zero after only few minutes of incubation. This behavior
fully resembles that of the human Glu104Asp mutant.
The deﬁcient mice show hemolytic anemia in homozygous
condition. Accordingly, signiﬁcant deviations from the wild-type
were observed for the values of hematocrit, hemoglobin, the number
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hemoglobin concentration and spleen weight [25].
The activity decrease was much less in other tissues, especially in
liver, kidney or brain (about 50%), than in blood [25]. This
phenomenon resembles the case when signiﬁcantly higher TPI
activity was measured in the lymphocyte lysates of compound
heterozygote patients carrying the Phe240Leu and the Glu145Stop
mutations than in their hemolysates [10,26]. A possible explanation
for this difference is that the decreased enzyme activity/level caused
by the instability of the mutant TPI is not restored due to the lack of
synthesis in mature erythrocytes, whereas enzyme synthesis would
maintain near-normal enzyme activity in other tissues/cells. There-
fore, the data obtained with the mouse model carrying Asp49Gly
mutation in TPI reinforced the notions based on data obtained in other
intracellular milieu (with recombinant enzymes, human blood
sample and yeast model) that the mutation at the dimer interface
results in instability of the dimeric enzyme causing its dissociation
into inactive monomers with concomitant impairment of the enzyme
activity.
6. Nature of mutations vs. clinical symptoms: TPI deﬁciency as a
conformational disease
The data accumulated in the past seems to show a correlation
between the nature of the mutations and the clinical symptoms. A
good example for this issue is the propositus carrying the Ile170Val
mutation in the active site region, who is free of neurological
symptoms. Therefore, it was suggested that structural changes rather
than abnormal catalysis might play an important role in the
generalized clinical manifestations of TPI deﬁciency [8]. The new
data corroborate this hypothesis, especially concerning the signiﬁ-
cance of the altered quaternary structure, i.e. the mutation induced
instability of the TPI dimer. Comparing the clinical symptomswith the
data of cell extracts, of the yeast model system, of recombinant
enzymes and of structural modeling, we can conclude that the
aberrant dimerization is the most important component in the
molecular basis of the illness. The rather the mutation inﬂuences
the dimer interface, the more serious the symptoms are.
Patients carrying mutations which do not inﬂuence the dimeriza-
tion process (Gly122Arg, Ile170Val, Phe240Leu) suffer from a
moderate form of TPI deﬁciency and are generally free of neurological
symptoms (Table 1). In the case of the Phe240Leu mutant, only one of
the two compound heterozygote patients developed neurological
symptoms, but even he is in stable condition in adulthood [10]. (Their
other mutation is a nonsense one at codon 145 (Glu145Stop) leading
to a truncated TPI.) Although Gly122Arg and Phe240Leu TPIs are
somewhat thermolabile, it may be caused by some alterations in the
secondary/tertiary but not in the quaternary structure.
Cys41Tyr and Val231Met mutations probably inﬂuence the
dimerization process, as suggested by prediction based on the 3D
structure of the native protein; the enzymes are thermolabile, and the
patients suffer from neurological disorder. However, they have
prolonged life span (N8 years) in comparison with the Glu104Asp
homozygote patients dying in infancy or early childhood. In this latter
case, it was unambiguously shown by variousmethods (prediction, X-
ray structure of the mutant TPI, in vitro stability assays, yeast two-
hybrid system) that the aberrant assembly of the mutant TPI subunits
is coupled with its inactivation and ﬁnally, through not yet revealed
steps, with the death of the patients. As we suggested previously, it
might be a consequence of the formation of toxic aggregates from the
misfolded protein in the brain. (“TPI deﬁciency as conformational
disease” hypothesis [9].) Taking into consideration that apart from
being necessary for enzyme activity, dimerization ensures also the
conformational stability of TPI (the folded monomer is only weakly
stabilized as compared to the unfolded monomer) [7], the unstable
monomer might display high aggregation ability. Our suggestion hasbeen further strengthened by recent data published by Guix et al. [27]
(see later). (Further human mutations, which are predicted to
inﬂuence the dimer interface, has been found only in a population
survey in a healthy heterozygote (Gly72Ala), or in a case not yet
studied in details (Ala62Asp).)
Decreased, even signiﬁcantly, catalytic activity per se does not
seem to lead to fatal consequences if the enzyme has stable
quaternary structure. It is not surprising if we take into account the
very high catalytic activity of the native enzyme. As we and others
showed, even the lowest TPI activity detected in the hemolysate of the
patients has to be enough to ensure normal glycolytic ﬂux [22,26,28].
In accordance with this, experimentally detected alterations in
glucose utilization, ATP and lactate production were found to be
unimpressive [2,10,22]. However, two observations should be noted.
First, that the equilibrium of triosephosphates is not achieved in
mutant erythrocytes resulting in a signiﬁcantly elevated DHAP
concentration in all cases [26]. Second, the relative activities of the
mutant enzymes (compared to that of the wild-type one) in
hemolysates (2–30%) were always less than those detected with
recombinant enzymes or in the yeast model system (30–100%). This
phenomenon was attributed to the decreased stability of the mutant
enzymes [29] and/or to intracellular interactions altering their
structure and function [11,30].
As we pointed out, a major hurdle to elucidate the pathomechan-
ism of TPI deﬁciency is the lack of brain tissues available for
experimental purposes [9]. The presence of the mutant protein
might result in the formation of toxic protein aggregates and/or the
impairment of energy metabolism. The ﬁrst possibility has arisen
because no energy deﬁcit has been demonstrated either in patients or
in the Drosophila model. However, neither of these possibilities has
been tested in brain. It is well demonstrated that in other
neurodegenerative diseases, such as Alzheimer's (AD), Parkinson's
or Huntington's diseases, unfolded or misfolded proteins form
aberrant protein–protein interactions that lead to the formation of
toxic protein aggregates causing neuronal dysfunction. The accumu-
lation of unfolded or misfolded proteins could impair energy
metabolism by mechanisms that are not fully understood. The
simultaneous investigation of these two aspects has been carried
out recently using mouse models for Huntington's disease: the
affected brain regions with pathological inclusions were identiﬁed
by immunohistochemistry and used for biochemical analysis of the
ATP-producing systems in the cytosolic and the mitochondrial
compartments [31]. Similar neurological and energetic analysis of
TPI mutant mice can be promising for the clariﬁcation of the
pathomechanism of TPI deﬁciency.
7. Relationship of TPI deﬁciency with other conformational
diseases
TPI was identiﬁed as one of the main proteins nitrotyrosinated by
nitric oxide synthase in AD patients [27,32,33] and in AD transgenic
mice [27]. Higher levels of nitro-TPI were detected in immunopreci-
pitates from hippocampus and frontal cortex of AD patients,
compared with healthy subjects [27]. Nitro-oxidative damage,
induced by amyloid β-peptide (Aβ), promoted the nitrotyrosination
of TPI in human neuroblastoma cells. Due to the nitration of tyrosines
164 and 208, close to the catalytic center and the ﬂexible loop, TPI
nitrotyrosination decreased about 10 times the enzyme activity and
triggered the production of the highly neurotoxic methylglyoxal, as a
by-product, in vitro [27]. Human embryonic kidney cells overexpres-
sing double mutant TPI modiﬁed at these two tyrosines (Tyr164Phe
and Tyr208Phe), which mimicked the effect of nitrotyrosination on
loop stability, showed high methylglyoxal production. In accordance
with these ﬁndings, methylglyoxal levels were signiﬁcantly higher in
AD brains than in healthy controls [27]. Glyoxalases cannot efﬁciently
detoxify the accumulated methylglyoxal, which leads to enhanced
Fig. 2. Tentative scheme of development of neurodegeneration in TPI deﬁciency. wTPI, wild-type TPI; mTPI, mutant TPI; GAP, glyceraldehyde-3-phosphate; ROS, reactive oxygen
species; NO, nitric oxide.
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accumulation of glycation adducts results in deleterious consequences
including oxidative stress (accumulation of reactive oxygen species)
(Fig. 2), DNA damage and apoptosis, in various diseases [35],
especially in the pathogenesis of degenerative neurological disorders
[36]. TPI was found among proteins become oxidatively modiﬁed in
early [37] and late [38] AD as well. These ﬁndings correlate with the
widespread glycation in the cortex and hippocampus from AD
transgenic mice [27].
These aspects have been arisen in TPI deﬁciency as well, where
the increased DHAP level leads to an accumulation of methyl-
glyoxal, composed from the accumulated DHAP non-enzymatically,
and results in the consequent enhanced level of AGEs [39] (Fig. 2).
Additionally, DHAP itself is also a glycating agent (Fig. 2), and it has
been shown recently that it is capable of condensing not only with
proteins altering their structure or function but also with GTP [40].
The abovementioned results by Guix et al. [27] suggest that
extensive methylglyoxal production can also occur directly due to
the functional defect of TPI. Moreover, TPI nitrotyrosination
probably occurs also in TPI deﬁciency since an 8-fold increase in
the mRNA level of nitric oxide synthase [26] (Fig. 2), the enzyme
responsible for nitration, and a 15-fold increase in urinary 3-
nitrotyrosine [39] were found in a Hungarian TPI-deﬁcient patient
carrying Phe240Leu and Glu145Stop mutations, the one with
neurological symptoms. Increased chronic oxidative stress was
also detected in the same patient [41].
It has also been demonstrated that nitrotyrosination induces the
aggregation of TPI [27] (Fig. 2). Furthermore, the nitrotyrosinated TPI
forms large structures with β-sheet folds that are induced in neurons
cultured in vitro, in the presence of Aβ and, importantly, are observed
in cortex from AD brain. The large size of nitrotyrosinated TPI
aggregates makes them resistant to degradation by the proteasome,
and these aggregates bind taumonomers and induced tau aggregation
to form paired helical ﬁlaments, the characteristic intracellular
hallmark of AD brains [27]. TPI co-localizes with tau in AD, but not
in healthy cortex and immunoprecipitates tau in both AD brains and
transgenic AD mice.
These ﬁndings corroborate the earlier ones that two fragments of
TPI are structurally homologous to the Aβ [42]. It was also shown thatone of these segments, with partial sequence homology to the Aβ, is
able to form amyloid in vitro. Moreover, TPI was recognized in pig
brain, mainly in the vessel walls of the hippocampus, by antibodies
raised against Aβ [43]. It was suggested that the crossreactivity
between Aβ and TPI was a synergic consequence of a partially
homologous amino acid sequence and their similar 3D conformational
epitopes.
One can hypothesize that modiﬁcations/mutations inﬂuencing the
structure of TPI may strengthen its likely inherent tendency for
aggregation. It was shown that some mutations in TPI, including
Glu104Asp and in less extent Phe240Leu, make it more prone to
associate with brain microtubules, which inﬂuences their polymeri-
zation and decreases the activity of the enzyme [11,30].
Altogether, the results reviewed in this paper show that the
development of the disease named as TPI deﬁciency from some
respects resembles conformational diseases which are initiated by
misfolded proteins. Investigations using TPI-deﬁcient mice and post
mortem human brain samples can further support this view and will
serve as an effective framework in order to understand the nature of
TPI deﬁciency at molecular level.Acknowledgements
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